Thioctic Acid Treatment for Mitochondrial Myopathy
thioctic acid
Metabolic Diseases+12
+ Muscular Diseases
+ Musculoskeletal Diseases
Treatment Study
Summary
Study start date: October 1, 1995
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: The patient receives one thioctic acid tablet 3 times a day. If patient experiences no side effects after 1 week, 2 tablets are administered and given 3 times a day over 3 months for compassionate use. The patient is followed at weeks 3, 8, and 12.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.1 patient to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Male
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Long standing ophthalmoparesis and fatiguable weakness of the limbs Mild ataxia and no central nervous system involvement History of mitochondrial DNA deletion and a measurable biochemical defect of the respiratory chain Steady deterioration in skeletal muscle mass and power over 5 years --Prior/Concurrent Therapy-- Previous participation in studies of muscle disease natural history (CRC Protocol 183A)